We would like to inform all participants, speakers, and attendees that the ICPOC 2026 event scheduled during November 23-25, 2026 in Singapore and Online has been postponed. The decision has been made to ensure the best possible experience for everyone involved. The new dates will be announced soon and updated on our website. We sincerely appreciate your understanding and continued support.
For any queries, please contact: [email protected]
We are excited to bring you an even bigger and better event!
Please stay tuned for updated details, which will be shared soon.
Oncology Therapeutic Strategy Lead, Novotech, United States
Dr. Tanja Obradovic has over 20 years of experience in Oncology pharmaceutical development. Her work encompasses all stages of clinical development and medical affairs gained from holding senior positions at Merck where she significantly contributed to Keytruda development, regulatory approvals and life cycle management across tumor types including melanoma, lung, women’s cancers and many other indications for over 10 years. Most recently she was leading development of drug and cell therapies at Takeda followed by leadership in oncology strategic drug development as VP of Drug Development Services, Scientific Affairs within Medical Strategy at ICON. She is currently on Advisory Boards for several Biotech companies and Consultant at Arc Nouvel Clinical Development LLC.
Oral Presentation (Virtual)
Oral Presentation (Virtual)
Title: Strategic development of novel cancer immunotherapies – medical strategy toward regulatory success
© 2026 Mathews International LLC. All rights reserved.
